LNA-Modified Antisense Oligonucleotide for TGF-beta Inhibition

The patent applies parameter changes by modifying the oligonucleotide structure with LNA (locked nucleic acid) modifications. This chemical modification enhances the binding affinity and stability of the antisense oligonucleotide to TGF-beta mRNA, thereby improving therapeutic effectiveness while maintaining a relatively simple treatment approach. The LNA modification changes the physical-chemical parameters of the oligonucleotide, resulting in superior efficacy compared to conventional ALK5 inhibitors and antibodies.

The patent employs composite materials by combining standard nucleotides with LNA (locked nucleic acid) modifications in the antisense oligonucleotide sequence. This composite structure integrates the specificity of natural nucleotides with the enhanced stability and affinity of LNA, achieving superior TGF-beta mRNA inhibition efficacy. The manufacturing process remains relatively simple as it involves standard oligonucleotide synthesis techniques with modified building blocks.

The patent applies the taking out principle by specifically extracting and targeting the harmful effects of TGF-beta through antisense oligonucleotide-mediated suppression of TGF-beta mRNA expression. By selectively inhibiting TGF-beta at the transcriptional level, the patent prevents the induction of inflammatory responses and tissue fibrosis while potentially preserving necessary extracellular matrix production functions. This specific targeting approach separates the harmful from the potentially beneficial effects of TGF-beta.